AI in Diagnostics Market Size, Share & Industry Analysis, By Component (Software & Services and Hardware), By Technology (Machine Learning, Natural Language Processing (NLP), and Others), By Application (Oncology, Cardiology, Neurology, Pulmonology, Infectious Diseases, and Others), By Modality (Medical Imaging {MRI, CT, X-ray, Ultrasound, PET/SPECT, and Others}, Digital Pathology, and Others), By End User (Hospitals & Clinics, Diagnostics & Imaging Centers, Pathology & Clinical Laboratories, and Others), and Regional Forecast, 2026-2034

The global AI in diagnostics market size was valued at USD 7.03 billion in 2025. The market is projected to grow from USD 10.12 billion in 2026 to USD 160.54 billion by 2034, exhibiting a CAGR of 41.27% during the forecast period.

AI-based diagnostic solutions are mainly used in diagnostic imaging, pathology, cardiology, oncology, ophthalmology, and in-vitro diagnostics. The market is expected to witness exponential growth in the coming years as healthcare providers are increasingly adopting artificial intelligence in daily operations. Additionally, increasing regulatory clearances, partnerships between technology companies and healthcare providers, and the expansion of enterprise AI platforms are strengthening commercial adoption across major markets.

• For instance, in April 2026, PathAI collaborated with MedStar Health to deploy PathAI’s AISight Dx digital pathology platform and AI applications across MedStar Health’s multi-site laboratory network. The deployment included AI algorithms such as ArtifactDetect and TumorDetect. The development highlights the growing transition of diagnostic AI solutions across hospital networks.

Major players, such as Amazon.com, Inc., Microsoft Corporation, NVIDIA Corporation, and Alphabet Inc., are actively participating in strategic collaborations and acquisitions to expand their offerings, facilitate interchangeability, enhance market access, and strengthen their market presence.

Download Free sample to learn more about this report.

AI IN DIAGNOSTICS MARKET TRENDS

Transition from Standalone AI Tools to Enterprise Diagnostic Platforms to Emerge as a Key Market Trend

One of the prominent emerging market trends is the shift toward enterprise-scale platforms capable of integrating multiple AI applications within a unified clinical workflow. Hospitals and diagnostic laboratories increasingly require solutions that can connect with existing information systems while supporting centralized case management, workflow orchestration, collaboration, and deployment of multiple AI algorithms. The transition enables healthcare providers to scale AI across departments and locations rather than implementing separate solutions for each diagnostic use case, thereby reducing integration complexity and improving operational efficiency. Major companies are introducing solutions in alignment with the trend.

• For instance, in December 2025, Aidoc partnered with WellSpan Health to scale its full aiOS enterprise AI platform across all nine hospitals and more than 250 care locations. The expansion included 21 new AI-powered care pathways across seven service lines, with aiOS integrated into WellSpan’s Epic EHR and imaging environment.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Pressure to Reduce Diagnostic Turnaround Times and Improve Clinical Workflow Efficiency to Drive Market Growth

Rising diagnostic volumes have resulted in increasing pressure on radiologists and pathologists, requiring healthcare systems to deliver faster clinical decisions. These factors are accelerating the adoption of AI-based diagnostic solutions, as demand for early and accurate diagnosis increases. Conventional diagnostic workflows often require specialists to manually review large volumes of imaging, pathology, and laboratory data, which can create reporting backlogs and delay treatment initiation. AI can automatically analyze diagnostic data, flag suspected abnormalities, prioritize high-risk cases, and support reporting, thereby allowing clinicians to focus attention on cases requiring immediate intervention. As hospitals increasingly seek to manage workforce constraints, the ability of AI to shorten interpretation times is becoming an important factor driving demand in the market.

• For instance, in August 2026, Mercy and Aidoc reported results from the deployment of Aidoc’s aiOS platform across Mercy’s health system. AI-based prioritization of urgent imaging cases reduced scan-to-result turnaround time from 19.8 hours to 1.3 hours. Mercy also deployed 13 AI imaging solutions across more than 50 hospitals, collectively supporting approximately 2.5 million imaging cases annually, demonstrating the potential of diagnostic AI to improve workflow efficiency at health-system scale.

MARKET RESTRAINTS

High Implementation and Integration Costs Limiting Adoption Across Smaller Healthcare Facilities to Hamper Market Growth

The deployment of AI-enabled diagnostic solutions requires significant upfront and recurring investments in software licensing, computing and cloud infrastructure, among other costs. In particular, AI applications must often be integrated with existing PACS, RIS, LIS, EHR, digital pathology, and other hospital information systems, which can require customized interfaces and dedicated IT resources. While large hospitals and integrated health systems can distribute these investments across substantial diagnostic volumes, smaller hospitals, independent diagnostic centers, and laboratories may find the total cost of ownership difficult to justify.

• For instance, in September 2025, a UCL-led evaluation of NHS England's USD 23.7 million program to introduce AI-powered diagnostic tools across 66 NHS trusts found substantial implementation delays. Researchers identified integration with aging and heterogeneous hospital IT systems, limited staff capacity, governance requirements, training, and the need for dedicated implementation resources among the major barriers. The case demonstrates that even a centrally funded large-scale AI program can encounter significant integration and resource burdens, indicating that these barriers may be more difficult to overcome in facilities with constrained IT budgets and personnel.

MARKET OPPORTUNITIES

Expansion of Reimbursement for Clinically Differentiated AI-Based Diagnostic Services to Offer Significant Growth Opportunities

The expansion of reimbursement represents a significant opportunity for the global AI in diagnostics market growth. Lack of dedicated payment pathways has historically limited hospitals’ ability to recover the incremental cost of adopting AI-based diagnostic technologies. As payers increasingly recognize AI services that provide measurable clinical value, AI can transition from being treated primarily as an operational expense to a separately identifiable, reimbursable diagnostic service. Dedicated reimbursement can improve the business case for hospitals and diagnostic centers, potentially improve purchasing decisions, encourage routine utilization, and enable vendors to develop sustainable per-procedure or recurring revenue models.

• For instance, effective January 1, 2026, AI-enabled quantitative coronary plaque analysis transitioned from temporary Category III CPT codes 0623T–0626T to permanent Category I CPT code 75577. CMS subsequently updated its Medicare billing and coding articles to incorporate the new code for AI-enabled CT-based coronary plaque analysis. This progression toward an established coding pathway demonstrates increasing recognition of clinically differentiated AI-enabled diagnostic services and provides a stronger foundation for wider reimbursement and commercial adoption.

MARKET CHALLENGES

Limited Interoperability with Existing Hospital and Diagnostic IT Infrastructure to Remain a Significant Challenge

Limited interoperability remains an important challenge for AI-powered diagnostics solutions, as they must operate within complex healthcare IT environments comprising PACS, RIS, LIS, EHRs, imaging archives, reporting systems, and equipment from multiple vendors. Differences in data formats, interfaces, workflow configurations, and legacy infrastructure can make it difficult to exchange images, clinical information, and AI-generated results between systems. The challenge becomes more significant as hospitals attempt to deploy multiple AI algorithms from different vendors across several diagnostic departments.

• For instance, in June 2026, Konica Minolta Healthcare Americas, Inc. partnered with DataFirst to provide advanced interoperability and DICOM-routing solutions for Exa PACS|RIS and Exa Teleradiology. The companies specifically highlighted that, even with established standards such as DICOM, healthcare organizations continue to face interoperability and routing issues when sharing imaging data across facilities and different PACS and RIS systems, with hospital and radiology-practice consolidation adding further complexity.

Segmentation Analysis

By Component

Recurring Deployment and Integration Requirements Supported Software & Services Segment Leadership

Based on the component, the market is categorized into software & services and hardware.

The software & services segment dominated the AI in diagnostics market share in 2025, as it is the primary analytical functionality of AI-based diagnostic solutions. Healthcare providers can deploy these solutions over their existing imaging, pathology, laboratory, and hospital IT infrastructure, reducing the requirement to purchase dedicated AI hardware for every new application. Also, software platforms require recurring licensing, cloud hosting, algorithm updates, interoperability support, implementation, and performance monitoring, generating continued expenditure throughout the product lifecycle. Such recurring revenue generation potential drives segmental dominance, further encouraging key companies to develop innovative products.

• For instance, in November 2025, Siemens Healthineers launched new AI-enabled radiology services designed to support workflows from scheduling and image acquisition through reporting. Its AI-Enablement Services generate customized summaries of clinically relevant imaging observations.

The hardware segment is expected to grow at a CAGR of 36.06% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Broad Diagnostic Applicability and Model Scalability Supported Machine Learning Dominance

Based on technology, the market is segmented into machine learning, natural language processing (NLP), and others.

In 2025, the machine learning segment captured the largest share in the market, as it provides the underlying pattern-recognition capability required for many high-value diagnostic applications. These technologies are particularly suited to large diagnostic datasets such as radiology images and digitized pathology slides, enabling models to recognize disease patterns that would otherwise require extensive manual interpretation. As a result, machine learning has achieved substantially broader clinical applicability across diagnostic specialties, supporting its larger market contribution.

• For instance, in May 2024, PathAI launched PLUTO, its pathology-focused foundation model developed using self-supervised machine learning. The model can be adapted across multiple pathology applications and can reduce the development time and cost of downstream AI tools compared with developing separate models from scratch.

The natural language processing (NLP) segment is projected to grow at a CAGR of 45.30% during the forecast period.

By Application

High Diagnostic Complexity and Biomarker-Driven Treatment Decisions Positioned Oncology at the Forefront

Based on application, the market is segmented into oncology, cardiology, neurology, pulmonology, infectious diseases, and others.

The oncology segment dominated the market in 2025. Cancer diagnosis involves multiple data-intensive stages, ranging from screening and lesion detection to histopathology, molecular profiling, biomarker identification, staging, prognosis, and treatment selection. These varied processes generate large volumes of data and elevate the demand for AI solutions in diagnostics to catalyze the process. AI can support tumor detection, classification, biomarker prediction, patient stratification, and treatment-response assessment, thereby extending its commercial applicability beyond initial diagnosis. Underscoring these factors, key companies are increasingly directing their resources toward new product launches.

• For instance, in January 2026, Tempus AI launched Paige Predict, an AI-powered digital pathology suite capable of analyzing routine H&E slides to predict the chances of 123 biomarkers and oncogenic molecular pathways across 16 cancer types. The solution covered cancers including NSCLC, prostate, breast, pancreatic, and colorectal cancer.

The cardiology segment is projected to grow at a CAGR of 41.68% during the forecast period.

By Modality

Large Imaging Volumes and Mature Digital Infrastructure Boosted Medical Imaging Leadership

Based on modality, the market is segmented into medical imaging, digital pathology, and others.

The medical imaging segment dominated the market in 2025, as radiology is among the earliest diagnostic specialties to generate large volumes of standardized digital data. High examination volumes and persistent radiologist workload pressures further create a measurable operational benefit from automated medical image analysis. Key companies are increasingly focusing on new product launches and their subsequent approval from regulatory bodies to capitalize on the segment’s growth potential.

• For instance, in February 2026, Qure.ai received FDA 510(k) clearance for six additional indications for its qXR-Detect computer-assisted chest X-ray solution. The clearance brought Qure.ai's portfolio to 26 FDA-cleared indications across nine X-ray and CT products. The expanding regulatory footprint across high-volume X-ray and CT workflows illustrated the maturity and breadth of medical imaging as a commercial application base for diagnostic AI.

The others segment is projected to grow at a CAGR of 53.89% over the forecast period.

By End User

High Patient Throughput and Enterprise-Scale AI Deployment Supported Hospital & Clinics Dominance

Based on end user, the market is segmented into hospitals & clinics, diagnostics & imaging centers, pathology & clinical laboratories, and others.

The hospitals & clinics segment dominated the market in 2025, as these facilities concentrate a substantial share of complex and acute diagnostic activity and operate multiple diagnostic departments. Large health systems also possess greater purchasing capacity, dedicated IT resources, clinical governance structures, and specialist teams needed to validate and monitor AI systems. As healthcare providers move from individual algorithms toward multi-specialty enterprise deployments, hospitals can generate considerably higher utilization and contract values than smaller standalone diagnostic facilities.

• For instance, in August 2026, Aidoc announced the formation of the Diagnostic AI Consortium with 12 major U.S. health systems, including Advocate Health, Cedars-Sinai Health System, Hartford HealthCare, Houston Methodist, Mercy, Mount Sinai Health System, Northwell Health, Northwestern Medicine, and others. The initiative demonstrated how large hospital networks are becoming central platforms for scaling diagnostic AI across extensive patient populations and clinical workflows.

The pathology & clinical laboratories segment is projected to grow at a CAGR of 43.53% over the forecast period.

AI in Diagnostics Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America was valued at USD 2.54 billion in 2024 and maintained its leading position with a value of USD 3.58 billion in 2025. Rapid hospital adoption of AI-enabled imaging and clinical decision-support solutions and strong digital health infrastructure are fueling market expansion in the region.

U.S. AI in Diagnostics Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 4.66 billion in 2026, accounting for roughly 45.99% of global revenues.

Europe

Europe is projected to grow at a CAGR of 38.09% in the coming years. The region is set to reach a valuation of USD 1.99 billion in 2026, becoming the third-largest market by region. The region is witnessing growth due to wider digitization of radiology and pathology workflows, increasing implementation of AI across public healthcare systems, and strong regulatory emphasis on validated medical AI solutions.

U.K. AI in Diagnostics Market

The U.K. market is estimated at USD 0.34 billion in 2026, accounting for roughly 3.31% of global revenues.

Germany AI in Diagnostics Market

The market in Germany is projected to reach approximately USD 0.47 billion in 2026, equivalent to around 4.69% of global revenues.

Asia Pacific

Asia Pacific is estimated to reach USD 2.30 billion in 2026 and secure the second-largest position in the market. The Asia Pacific market is expanding rapidly due to large patient populations, rising diagnostic volumes, shortages of radiologists and other specialists, and growing investment in digital healthcare infrastructure.

Japan AI in Diagnostics Market

The Japanese market in 2026 is estimated at around USD 0.51 billion, accounting for approximately 5.06% of global revenues.

China AI in Diagnostics Market

The market in China is projected to be among the largest globally, with 2026 revenues estimated at around USD 0.86 billion, accounting for approximately 8.47% of global revenues.

India AI in Diagnostics Market

The Indian market in 2026 is estimated at around USD 0.35 billion, accounting for roughly 3.49% of global revenues.

Latin America and Middle East & Africa

Latin America is expected to witness moderate growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.43 billion in 2026. Growth is supported by increasing modernization of hospital and diagnostic infrastructure, expansion of private healthcare networks, and rising adoption of cloud-based AI solutions that require lower upfront infrastructure investment. In the Middle East & Africa, the GCC is set to reach USD 0.13 billion in 2026.

South Africa AI in Diagnostics Market

The South African market is projected to reach approximately USD 0.04 billion in 2026, accounting for roughly 0.43% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Focus on AI-Enabled Product Expansion and Enterprise Deployment to Strengthen Market Position

The global AI in diagnostics market has a competitive and moderately fragmented structure, with companies such as Siemens Healthineers, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc. (Google), Amazon.com, Inc., Aidoc, PathAI, and Tempus AI establishing strong positions across medical imaging, digital pathology, autonomous diagnostics, and diagnostic AI infrastructure. The competitive position of these companies is supported by continuous product innovation, regulatory clearances, integration with existing diagnostic workflows, strategic healthcare partnerships, and expansion of enterprise-scale AI platforms. Companies are increasingly focusing on moving AI solutions from individual diagnostic algorithms toward broader platforms that can support multiple clinical applications, enabling greater adoption across hospitals, laboratories, and diagnostic centers.

• For instance, in August 2026,  Alphabet Inc. (Google) partnered with Abbott to help people manage their health. The partnership combined glucose insights from Abbott's Lingo wearable with Google's expertise in artificial intelligence (AI) and consumer technology. The collaboration brought metabolic health insights into people's daily routines through an AI-powered experience helping them better understand how daily behaviors influence their overall well-being.

Other notable players in the global market include Digital Diagnostics and Qure.ai. These companies are expected to prioritize new algorithm launches, regulatory approvals, expansion into additional diagnostic indications, hospital partnerships, and integration of AI capabilities to strengthen their market presence during the forecast period for the global market.

LIST OF KEY AI IN DIAGNOSTICS COMPANIES PROFILED

• com, Inc. (U.S.)
• Microsoft Corporation (U.S.)
• NVIDIA Corporation (U.S.)
• Alphabet Inc. (Google)
• Siemens Healthineers AG (Germany)
• Aidoc (Israel)
• PathAI, Inc. (U.S.)
• Digital Diagnostics Inc. (U.S.)
• Tempus AI (U.S.)
• ai. (India)

KEY INDUSTRY DEVELOPMENTS

• August 2026: Tempus AI, Inc. received clearance from the U.S. FDA for Tempus ECG-PH, an AI-enabled software device designed to analyze standard 12-lead ECG recordings for signs associated with pulmonary hypertension. The development strengthens the company's presence in AI-assisted cardiovascular diagnostics and expands the application of AI beyond imaging and pathology workflows.
• July 2026: PathAI, Inc. launched AISight Dx v2.21, a U.S. FDA-cleared digital pathology platform. The update introduced customizable dashboards, AI-based case prioritization, enhanced slide-review functionality, improved data organization, and enterprise-level workflow configuration.
• May 2026: Tempus AI, Inc. launched the ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer, marking the first externally developed digital pathology algorithm made clinically available through the Tempus ecosystem. The development broadens the use of AI-based pathology for patient stratification and supports more personalized diagnostic and treatment decision-making in oncology.
• February 2026: ai launched its qXR-Detect computer-assisted chest X-ray solution and received FDA 510(k) Class II clearance for six additional indications. The expansion strengthens the availability of AI-based interpretation tools for high-volume chest radiography and broadens Qure.ai's commercial diagnostic portfolio in the U.S.
• November 2025: Siemens Healthineers launched Optiq AI, a new AI-powered imaging chain for its latest interventional imaging systems. The development illustrates the increasing movement of diagnostic AI upstream into image acquisition and reconstruction, expanding AI's role beyond post-acquisition image interpretation.

REPORT COVERAGE

The global AI in diagnostics market report provides market size estimates and forecasts for all key segments covered in the study. The market outlook also evaluates the key drivers, restraints, opportunities, challenges, and emerging trends expected to influence market growth during the forecast period. The report also presents a comprehensive global market analysis and a detailed competitive landscape covering estimated market shares, AI diagnostic product portfolios, platform capabilities, regulatory approvals, clinical validation strategies, strategic partnerships, collaborations, product launches, geographic presence, recent developments, and profiles of key market participants.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation

Research Methodology

1. Bottom-Up Approaches

Approach 1:  Diagnostic Procedure Volume & AI-Addressable Examination Analysis

• Collection of country-level diagnostic procedure volumes across CT, MRI, X-ray, ultrasound, PET/SPECT, digital pathology, laboratory diagnostics, and other AI-addressable diagnostic workflows.
• Assessment of major markets including the U.S., Canada, Germany, U.K., France, China, Japan, India, Australia, Brazil, GCC countries, and other key markets.
• Estimation of the proportion of procedures addressable by AI based on digital infrastructure availability, AI eligibility of examinations, existing AI penetration, and clinical adoption.
• Estimation of AI-enabled study volumes across hospitals & clinics, diagnostic & imaging centers, pathology laboratories, and other diagnostic settings.
• Application of per-study fees, annual subscriptions, enterprise licenses, platform fees, and service revenues to estimate AI-attributable market revenue.
• For AI embedded within diagnostic equipment, only the incremental AI-attributable revenue.

Approach 2: Installed Base & AI Attach-Rate Analysis

• Estimation of the installed base of CT, MRI, X-ray, ultrasound, pathology scanners, laboratory platforms, and other AI-compatible diagnostic systems across major countries.
• Assessment of AI penetration and attach rates across the installed diagnostic equipment base.
• Estimation of the number of AI algorithms/applications deployed per system, utilization levels, and diagnostic examinations processed annually.
• Application of software subscription, per-procedure, enterprise platform, maintenance, and recurring monetization assumptions.
• Adjustment for differences in digital maturity, hospital infrastructure, installed-base utilization, and AI adoption across countries and regions.
• Aggregation of country-level AI-attributable revenues to estimate the regional and global market size.

Approach 3:  Company Revenue & Market Participation Analysis

• Analysis of major market participants including Siemens Healthineers, NVIDIA, Microsoft, Amazon, Google, Aidoc, Tempus AI, PathAI, Qure.ai, Digital Diagnostics, and other diagnostic AI companies.
• Collection of company revenues from annual reports, SEC filings, investor presentations, earnings releases, and product disclosures.
• Mapping of total company revenue to the relevant healthcare, imaging, digital pathology, AI platform, diagnostic software, or other applicable business segment.
• Estimation of the proportion of segment revenue specifically attributable to AI-enabled diagnostic products, platforms, algorithms, and services.
• Cross-validation of company-derived revenues against product portfolios, installed base, geographic presence, partnerships, and commercial deployments.
• Adjustment to avoid double counting between cloud infrastructure providers, imaging OEMs, platform vendors, and diagnostic algorithm developers.

2. Top Down Approaches

Approach 1: Analysis of Parent & Adjacent Markets and Institutional Data

• Assessment of relevant parent and adjacent markets including medical imaging, digital pathology, molecular/laboratory diagnostics, diagnostic software, healthcare IT, and AI-enabled healthcare technologies.
• Estimation of the portion of these market pools attributable specifically to AI diagnostics using AI penetration, software adoption, attach rates, product availability, and vendor participation.
• Regional allocation based on diagnostic procedure volumes, imaging/pathology installed base, healthcare expenditure, digital-health maturity, specialist availability, and AI adoption levels.
• Consideration of regulatory approvals, reimbursement environment, public/private AI investment, hospital digitization, and enterprise AI deployment across major countries.
• Validation of top-down estimates against the procedure-volume model, installed-base model, company-revenue model, and country-level market estimates.
• Parent-market constraints were applied to ensure AI-attributable revenues did not exceed the economically addressable diagnostic ecosystem or include underlying scanner, cloud, laboratory instrument, or testing revenues.

3. List of Key Sources

• Company annual reports, SEC filings, investor presentations, earnings releases, and product-specific disclosures
• Company websites, product portfolios, press releases, partnerships, and commercial deployment announcements
• S. FDA AI-enabled medical device database, 510(k), De Novo, and related regulatory databases
• EMA/MDCG publications and European medical device regulatory documents
• PMDA, Japan
• NMPA, China
• CDSCO, India
• TGA, Australia
• Health Canada
• WHO, NIH, CDC, and other international and national public-health databases
• National health statistics and diagnostic procedure databases
• Radiology, pathology, laboratory medicine, cardiology, oncology, and other professional societies
• Peer-reviewed publications, clinical studies, and real-world evidence
• Hospital procurement databases, public tenders, reimbursement schedules, and government healthcare programs

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • Executives and business-development professionals of diagnostic AI companies
  • Product managers and commercial strategy executives
  • Medical imaging equipment manufacturers/OEMs
  • AI platform and enterprise diagnostic software providers
  • Digital pathology solution providers
  • Cloud and healthcare infrastructure companies
  • Specialist diagnostic algorithm developers
  • Sales, distribution, integration, and implementation partners

Demand Side Interviews: 40%

• Key Respondents:
  • Radiologists and imaging specialists
  • Pathologists and laboratory directors
  • Hospital CIOs/CMIOs and digital-health decision makers
  • Diagnostic and imaging-center administrators
  • Hospital procurement and purchasing teams
  • Oncologists, cardiologists, neurologists, pulmonologists, and other clinicians
  • Payers and reimbursement stakeholders
  • Public-health and healthcare-system representatives